GiwoTech: Pioneering AI-Driven Antivirals with Advanced Viral Simulations

Harnessing AI to Outsmart Viruses and Pave the Way for Next-Generation Antivirals

In the dynamic world of biotech startups, GiwoTech is carving out a niche with its revolutionary approach to combating viral diseases. Co-founded by Razvan Marinescu and Ashwin Lokapally, former postdocs at MIT with PhDs in Machine Learning for Healthcare and Developmental Biology respectively, GiwoTech harnesses the power of artificial intelligence to change the landscape of antiviral drug development.

Established in January 2022 and based in Delaware, GiwoTech recently bolstered its innovative endeavors with a $50,000 grant from the National Science Foundation (NSF). This funding supports their market research, pivotal for launching their product effectively. GiwoTech's ambition is to develop a new class of antivirals that specifically targets and blocks virus assembly—a novel approach in the fight against infectious diseases.

The startup’s focus is on creating detailed simulations of capsid assembly in viruses. Capsids are protein shells of viruses that protect viral genetic material and play a critical role in the virus's ability to infect host cells and replicate. By understanding and simulating these structures, GiwoTech aims to identify potential weak points where new antivirals could intervene to block the virus assembly process.

GiwoTech’s initial target is Hepatitis B, a significant global health challenge affecting millions worldwide. However, their research and development strategy includes plans to expand this technology to other viruses, potentially broadening the impact of their discoveries.

As one of the applicants for the 6th cohort of the Santa Cruz Accelerates accelerator program, GiwoTech stands out with its cutting-edge technology and high potential for impact in medical treatments. With its robust scientific foundation and strategic NSF backing, GiwoTech is on a trajectory to not only advance antiviral research but also transform patient outcomes by stopping viruses before they start.

With such groundbreaking work underway, GiwoTech exemplifies the potential of AI in healthcare, promising a future where viral infections are no longer a global health crisis.

Santa Cruz Accelerates

Over 45 startups have applied to the 6th cohort of Santa Cruz Accelerates. Each week, we will spotlight a few startups that have applied. 10 lucky startups will be accepted and announced in mid-July. If you are a startup, a mentor, or an investor, learn more at: Partners